Suggestions
Nishan de Silva
Nishan de Silva is a highly accomplished professional with a diverse educational background and extensive experience in various leadership roles within the pharmaceutical and biotech industry.
He holds a Bachelor of Arts in Biology from Harvard University, a Master of Business Administration in Management and Healthcare from The Wharton School, and a Doctor of Medicine in Medicine from the University of Pennsylvania School of Medicine.
Nishan currently serves as the Chief Executive Officer and Director at Afyx Therapeutics, showcasing his expertise in strategic leadership and business management.
Prior to his current role, he held prominent positions at renowned organizations such as Selecta Biosciences, Poseida Therapeutics, Ligand Pharmaceuticals, Protox Therapeutics, Allos Therapeutics, Hana Biosciences, and Transposagen Biopharmaceuticals.
His illustrious career also includes significant contributions as the Chief Financial Officer, President, Chief Operating Officer, Vice President of Finance and Strategy, and Vice President of Corporate Development at various companies within the industry.
Nishan has a proven track record of success, having demonstrated his capabilities in financial management, corporate development, strategic planning, and executive decision-making.
With a background in both healthcare and business administration, Nishan de Silva's expertise lies at the intersection of medicine, management, and biotechnology, making him a valuable asset in the pharmaceutical sector.
His experience as a Principal at Warburg Pincus Llc, an Associate at Sprout Group, and an Engagement Manager at Mckinsey & Company further highlights his versatility and deep understanding of the industry.
Nishan's strong academic foundation, coupled with his extensive professional experience, positions him as a prominent figure in the field of biopharmaceuticals and healthcare management.
He continues to make significant contributions to the industry, driving innovation and growth in his current role at Afyx Therapeutics.
